Claims
- 1. A method for specifically delivering an effector molecule to a tumor cell bearing an IL-13 receptor, said method comprising:
providing a chimeric molecule comprising said effector molecule attached to a targeting molecule that specifically binds to an IL-13 receptor; and contacting said tumor with said chimeric molecule; wherein said chimeric molecule specifically binds to a tumor cell.
- 2. The method of claim 1, wherein said targeting molecule is IL-13.
- 3. The method of claim 1, wherein said targeting molecule is an anti-IL-13 receptor antibody.
- 4. The method of claim 1, wherein said targeting molecule is a circularly permuted IL-13.
- 5. The method of claim 1, wherein said tumor is selected from the group consisting of a carcinoma.
- 6. The method of claim 1, wherein said tumor is selected from the group consisting of a renal cell carcinoma, a glioma, a medulloblastoma, a renal cell carcinoma, and a Kaposi's sarcoma.
- 7. The method of claim 1, wherein said effector molecule is selected from the group consisting of a cytotoxin, a label, a radionuclide, a drug, a liposome, a ligand, and an antibody.
- 8. The method of claim 7, wherein said effector molecule is a Pseudomonas exotoxin.
- 9. The method of claim 8, wherein chimeric molecule is a fusion protein.
- 10. The method of claim 9, wherein said a fusion protein is IL-13-PE38QQR.
- 11. The method of claim 9, wherein said a fusion protein is cpIL-13-PE4E.
- 12. The method of claim 9, wherein said a fusion protein is IL-13-PE4E.
- 13. The method of claim 9, wherein said a fusion protein is cpIL-13-PE4E.
- 14. A method for impairing growth of tumor cells bearing an IL-13 receptor, said method comprising contacting said tumor with a chimeric molecule comprising:
a targeting molecule that specifically binds a human IL-13 receptor; and an effector molecule selected from the group consisting of a cytotoxin, a radionuclide, a ligand and an antibody; wherein said chimeric molecule specifically binds to a tumor cell.
- 15. The method of claim 14, wherein said targeting molecule is an antibody that specifically binds a human IL-13 receptor.
- 16. The method of claim 14, wherein said targeting molecule is a human IL-13.
- 17. The method of claim 14, wherein said targeting molecule is a circularly permuted human IL-13.
- 18. The method of claim 16, 17, wherein said effector molecule is a cytotoxin.
- 19. The method of claim 18, wherein said cytotoxin is selected from the group consisting of Pseudomonas exotoxin, ricin, abrin and Diphtheria toxin.
- 20. The method of claim 19, wherein chimeric molecule is a single-chain fusion protein.
- 21. The method of claim 19, wherein said cytotoxin is a Pseudomonas exotoxin.
- 22. The method of claim 21, wherein said Pseudomonas exotoxin is PE38QQR.
- 23. The method of claim 21, wherein said Pseudomonas exotoxin is PE4E.
- 24. The method of claim 16, 17, wherein said tumor cell growth is tumor cell growth in a human.
- 25. The method of claim 24, wherein said contacting comprises administering said chimeric molecule to the human intravenously, into a body cavity, or into a lumen or an organ.
- 26. A method for detecting the presence or absence of a tumor, said method comprising contacting said tumor with a chimeric molecule comprising:
a targeting molecule that specifically binds a human IL-13 receptor; and a detectable label; and detecting the presence or absence of said label.
- 27. A vector comprising a nucleic acid sequence encoding a chimeric fusion protein comprising an IL-13 or circularly permuted IL-13 attached to a polypeptide wherein said chimeric fusion protein specifically binds to a tumor cell bearing an IL-13 receptor.
- 28. The vector of claim 27, wherein said nucleic acid sequence encodes an IL-13-PE fusion protein.
- 29. The vector of claim 27, wherein said nucleic acid sequence encodes a cpIL-13-PE fusion protein.
- 30. The vector of claim 28, 29, wherein said nucleic acid sequence encodes a fusion protein selected from the group consisting of IL-13-PE38QQR, cpIL-13-PE38QQR, IL-13-PE4E, and cpIL-13-PE4E.
- 31. A host cell comprising a nucleic acid sequence encoding a chimeric fusion protein comprising an IL-13 or a circularly permuted IL-13 attached to a polypeptide wherein said chimeric fusion protein specifically binds to a tumor cell bearing an IL-13 receptor.
- 32. The host cell of claim 31, wherein said nucleic acid sequence encodes an IL-13-PE fusion protein.
- 33. The vector of claim 32, wherein said nucleic acid sequence encodes a fusion protein selected from the group consisting of IL-13-PE38QQR, cpIL-13-PE38QQR, IL-13-PE4E, and cpIL-13-PE4E.
- 34. A chimeric molecule that specifically binds a tumor cell bearing an IL-13 receptor, said chimeric molecule comprising a cytotoxic molecule attached to a targeting molecule that specifically binds an IL-13 receptor.
- 35. The composition of claim 34, 34, wherein said targeting molecule is human IL-13.
- 36. The composition of claim 34, 34, wherein said cytotoxin is selected from the group consisting of Pseudomonas exotoxin, ricin, abrin and Diphtheria toxin.
- 37. The composition of claim 35, wherein chimeric molecule is a single-chain fusion protein.
- 38. The method of claim 37, wherein said cytotoxin is a Pseudomonas exotoxin.
- 39. The composition of claim 38, 39, 41, 46, wherein said Pseudomonas exotoxin is PE38QQR or PE4E.
- 40. A chimeric molecule that specifically binds a tumor cell bearing an IL-13 receptor, said chimeric molecule comprising an effector molecule attached to an antibody that specifically binds an IL-13 receptor.
- 41. The composition of claim 40, wherein said effector molecule is selected from the group consisting of a cytotoxin, a label, a radionuclide, a drug, a liposome, a ligand, and an antibody.
- 42. A pharmacological composition comprising a pharmaceutically acceptable carrier and a chimeric molecule, said chimeric molecule comprising:
an effector molecule attached to
a targeting molecule that specifically binds to an IL-13 receptor.
- 43. The composition of claim 42, wherein said targeting molecule is selected from the group consisting of IL-13, and circularly permuted IL-13.
- 44. The composition of claim 43, wherein said effector molecule is selected from the group consisting of a cytotoxin, a label, a radionuclide, a drug, a liposome, a ligand, and an antibody.
- 45. The composition of claim 44, wherein chimeric molecule is a single-chain fusion protein.
- 46. The composition of claim 45, wherein said Pseudomonas exotoxin is PE38QQR or PE4E.
RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. application Ser. No. 08/404,685 filed Mar. 15, 1995 which is incorporated herein by reference for all purposes.
Continuations (1)
|
Number |
Date |
Country |
Parent |
08913370 |
Feb 1998 |
US |
Child |
10318608 |
Dec 2002 |
US |